Voyager Short Term Debt vs Net Debt Analysis
VYGR Stock | USD 5.43 0.07 1.31% |
Voyager Therapeutics financial indicator trend analysis is much more than just breaking down Voyager Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Voyager Therapeutics is a good investment. Please check the relationship between Voyager Therapeutics Short Term Debt and its Net Debt accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Voyager Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Voyager Stock, please use our How to Invest in Voyager Therapeutics guide.
Short Term Debt vs Net Debt
Short Term Debt vs Net Debt Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Voyager Therapeutics Short Term Debt account and Net Debt. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Voyager Therapeutics' Short Term Debt and Net Debt is -0.1. Overlapping area represents the amount of variation of Short Term Debt that can explain the historical movement of Net Debt in the same time period over historical financial statements of Voyager Therapeutics, assuming nothing else is changed. The correlation between historical values of Voyager Therapeutics' Short Term Debt and Net Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Short Term Debt of Voyager Therapeutics are associated (or correlated) with its Net Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Debt has no effect on the direction of Short Term Debt i.e., Voyager Therapeutics' Short Term Debt and Net Debt go up and down completely randomly.
Correlation Coefficient | -0.1 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Short Term Debt
Net Debt
The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.Most indicators from Voyager Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Voyager Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Voyager Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Voyager Stock, please use our How to Invest in Voyager Therapeutics guide.At this time, Voyager Therapeutics' Tax Provision is relatively stable compared to the past year. As of 11/22/2024, Issuance Of Capital Stock is likely to grow to about 32.7 M, while Sales General And Administrative To Revenue is likely to drop 0.14.
2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 111.0M | 91.7M | 35.8M | 34.0M | Cost Of Revenue | 73.8M | 6.2M | 92.2M | 61.1M |
Voyager Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Voyager Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Voyager Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 354.8M | 261.6M | 193.9M | 159.4M | 351.3M | 211.3M | |
Other Current Liab | 21.5M | 14.2M | 11.0M | 7.8M | 16.8M | 10.4M | |
Total Current Liabilities | 76.0M | 26.8M | 51.0M | 72.6M | 64.5M | 38.3M | |
Total Stockholder Equity | 99.5M | 154.3M | 95.1M | 59.0M | 236.3M | 248.1M | |
Net Debt | (51.9M) | (56.8M) | (73.3M) | (75.8M) | (48.5M) | (50.9M) | |
Retained Earnings | (312.6M) | (275.9M) | (347.1M) | (393.5M) | (261.2M) | (274.2M) | |
Accounts Payable | 4.1M | 634K | 574K | 2.6M | 1.6M | 1.5M | |
Cash | 86.0M | 104.4M | 117.4M | 99.0M | 68.8M | 62.9M | |
Non Current Assets Total | 50.1M | 63.8M | 57.2M | 34.9M | 31.6M | 31.2M | |
Non Currrent Assets Other | 1.7M | 537K | 1.8M | 1.5M | (1.0) | (0.95) | |
Other Assets | 1.7M | 2.3M | 1.8M | 1.5M | 1.0 | 0.95 | |
Cash And Short Term Investments | 281.5M | 181.1M | 132.5M | 118.8M | 230.9M | 167.6M | |
Common Stock Shares Outstanding | 35.9M | 37.3M | 37.7M | 38.4M | 44.6M | 29.7M | |
Liabilities And Stockholders Equity | 354.8M | 261.6M | 193.9M | 159.4M | 351.3M | 211.3M | |
Non Current Liabilities Total | 179.2M | 80.5M | 47.8M | 27.7M | 50.5M | 60.7M | |
Total Liab | 255.2M | 107.3M | 98.8M | 100.3M | 115.0M | 98.6M | |
Total Current Assets | 304.7M | 197.8M | 136.7M | 124.5M | 319.7M | 180.1M | |
Other Liab | 148.3M | 37.1M | 9.2M | 7.5M | 8.6M | 8.1M | |
Net Tangible Assets | 99.5M | 154.3M | 95.1M | 59.0M | 67.9M | 106.6M | |
Property Plant And Equipment Net | 46.5M | 61.5M | 55.4M | 33.3M | 30.0M | 29.0M | |
Short Term Investments | 195.5M | 76.7M | 15.1M | 19.9M | 162.1M | 94.4M | |
Other Current Assets | 2.0M | 6.9M | 3.4M | 5.0M | 4.4M | 2.8M | |
Other Stockholder Equity | 412.2M | 430.3M | 442.3M | 452.7M | 497.5M | 339.2M | |
Property Plant And Equipment Gross | 46.5M | 25.4M | 71.3M | 50.5M | 45.0M | 30.3M | |
Accumulated Other Comprehensive Income | (104K) | (134K) | (138K) | (219K) | (48K) | (50.4K) | |
Property Plant Equipment | 46.5M | 25.4M | 21.9M | 17.9M | 20.5M | 18.2M | |
Current Deferred Revenue | 47.2M | 7.7M | 42.1M | 65.8M | 42.9M | 31.3M | |
Net Receivables | 19.0M | 8.0M | 748K | 639K | 84.5M | 88.7M | |
Retained Earnings Total Equity | (312.6M) | (275.9M) | (347.1M) | (393.5M) | (354.2M) | (371.9M) | |
Capital Surpluse | 412.2M | 430.3M | 442.3M | 452.7M | 520.6M | 384.1M | |
Inventory | 2.2M | 6.9M | 1.7M | 779K | 1.0 | 1.05 | |
Net Invested Capital | 99.5M | 154.3M | 95.1M | 59.0M | 236.3M | 129.6M | |
Net Working Capital | 228.6M | 171.0M | 85.7M | 51.9M | 255.2M | 267.9M |
Pair Trading with Voyager Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Voyager Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Voyager Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Voyager Stock
The ability to find closely correlated positions to Voyager Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Voyager Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Voyager Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Voyager Therapeutics to buy it.
The correlation of Voyager Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Voyager Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Voyager Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Voyager Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Voyager Stock Analysis
When running Voyager Therapeutics' price analysis, check to measure Voyager Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Voyager Therapeutics is operating at the current time. Most of Voyager Therapeutics' value examination focuses on studying past and present price action to predict the probability of Voyager Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Voyager Therapeutics' price. Additionally, you may evaluate how the addition of Voyager Therapeutics to your portfolios can decrease your overall portfolio volatility.